针灸治疗成人镰状细胞病慢性疼痛:混合方法预试验
本研究为单臂前瞻性预试验,纳入6名伴有≥3个月慢性疼痛的成人镰状细胞病(SCD)患者,评估针灸治疗慢性疼痛的可行性与可接受性。针灸计划每周2次、共5周、每次30分钟;因COVID-19研究暂停,部分参与者未完成10次方案,但完成率高且无漏约。干预后所有参与者疼痛强度和疼痛干扰均降低,方案可接受性问卷平均得分82%,无不良事件报告。
要点
- 成人SCD慢性疼痛患者接受针灸可行且可接受,无不良事件。
- 干预后所有参与者疼痛强度与疼痛干扰均降低。
- 方案可接受性问卷平均得分82%。
核心结论
- 在成人镰状细胞病(SCD)患者中实施针灸治疗慢性疼痛是可行且可接受的。
- 本研究可为更大规模随机对照试验提供参考,以评估针灸减轻成人SCD慢性疼痛的效果。
研究设计与样本
- 单臂前瞻性预试验,纳入6名年龄>18岁、慢性疼痛≥3个月的成人SCD患者。
- 针灸计划每周2次、共5周、每次30分钟,在伊利诺伊大学芝加哥分校护理学院针灸治疗实验室进行。
- 基线及干预后测量疼痛强度、疼痛干扰及其他症状,干预后完成半结构化访谈和方案可接受性问卷。
主要发现
- 6名参与者(平均年龄52.5岁,均为黑人)入组;研究因COVID-19暂停,并非所有参与者完成10次方案,但完成率高且无漏约。
- 1名参与者因与针灸无关的住院未完成研究;无不良事件报告。
- 在基线后4-5周干预完成时,所有参与者疼痛强度和疼痛干扰均降低。
- 方案可接受性问卷平均得分为82%。
关键数值与推荐
- 参与者报告慢性疼痛≥3个月且年龄>18岁。
- 针灸方案为每周2次、共5周、每次30分钟。
- 方案可接受性问卷平均得分为82%。
临床怎么用
- 对于成人SCD慢性疼痛患者,可考虑将针灸作为可行且可接受的辅助治疗选项。
- 实施时需注意因外部因素(如COVID-19)导致方案中断的可能,并做好应对。
局限性
- 单臂预试验,样本量小(6名参与者),无对照组。
- 研究因COVID-19暂停,并非所有参与者完成10次针灸方案。
- 1名参与者因与针灸无关的住院未完成研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic pain is a common symptom experienced among patients with sickle cell disease (SCD). Our aims were to assess the feasibility and acceptability of performing acupuncture for the treatment of chronic pain in adults with SCD. METHODS: This was a single-arm, prospective pilot study of six adults with SCD. Participants reported ⩾ 3 months of chronic pain and were > 18 years of age. Per protocol, acupuncture was to be administered twice per week for 5 weeks, for 30 min per session. All treatments were performed in the acupuncture treatment laboratory at the University of Illinois Chicago College of Nursing. Pain intensity, pain interference, and other symptoms were measured at baseline and after the intervention. Participants completed a semi-structured interview and a protocol acceptability questionnaire after the acupuncture intervention. RESULTS: Six participants (mean age 52.5 years, six Black) were enrolled. Although the study was suspended due to COVID-19 and not all participants completed the 10-session protocol, completion rates were high with no missed appointments. One participant did not complete the study due to hospitalization unrelated to acupuncture. No adverse events were reported. At completion of the intervention at 4-5 weeks post-baseline, all participants had reduced pain intensity and pain interference. The mean acceptability score on the protocol acceptability questionnaire was 82%. CONCLUSION: It was feasible and acceptable to implement acupuncture in adults with SCD. This study can be used to guide a larger randomized controlled trial to evaluate the effect of acupuncture on reducing chronic pain in adults with SCD.Trial registration number: NCT04156399 (ClinicalTrials.gov).
引用
- Li H, Patil CL, Molokie RE, et al. Acupuncture for chronic pain in adults with sickle cell disease: a mixed-methods pilot study. Acupunct Med. 2021. PMID: 34080441. doi:10.1177/09645284211017303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。